The European Medicines Agency (EMEA) has been formally notified by Janssen-Cilag International N.V. of its decision to withdraw its application for an extension of indication for the centrally authorized medicine Invega (paliperidone) prolonged-release tablets. Invega was expected to be used for the...
Janssen-Cilag International N.V. Withdraws Its Application For An Extension Of Indication For Invega (paliperidone)
Indiana University Neuroscientists Identify Bipolar Disorder Genes, Pathways
Neuroscientists at the Indiana University School of Medicine have created the first comprehensive map of genes likely to be involved in bipolar disorder, according to research published online Nov. 21 in the American Journal of Medical Genetics. The researchers combined data from the latest large-scale...
Repligen Initiates Phase 2b Clinical Trial Of RG2417 In Bipolar Disorder
Repligen Corporation (Nasdaq: RGEN) announced that the Company has initiated a Phase 2b clinical trial to evaluate the use of RG2417, an oral formulation of uridine, in patients with bipolar depression. This Phase 2b study is a multi-center, randomized, double-blind, placebo-controlled clinical trial...
Bipolar Disorder Involves A Lower Quality Of Both Mental And Physical Life, Even In Periods Of Normality
A study carried out in the Institute of Neurosciences of the University of Granada (Spain) and the Mental Health Unit of the Hospital Neurotraumatológico of Jaen (Spain) has evaluated the quality of life of patients suffering from bipolar disorder (BD), in comparison with the general population, and...
Bipolar Disorder Involves A Lower Quality Of Both Mental And Physical Life, Even In Periods Of Normality
A study carried out in the Institute of Neurosciences of the University of Granada (Spain) and the Mental Health Unit of the Hospital Neurotraumatológico of Jaen (Spain) has evaluated the quality of life of patients suffering from bipolar disorder (BD), in comparison with the general population, and...
Forest Laboratories, Inc. And Gedeon Richter Plc Announce Positive Phase II Results With The Investigational Antipsychotic Cariprazine
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced preliminary top-line results from a phase II clinical trial of cariprazine (RGH-188), an investigational antipsychotic, in patients with acute mania associated with bipolar I disorder. For the primary endpoint, the Young Mania Rating...
FDA Approves First Generic Divalproex Sodium To Treat Seizures, Migraine Headaches And Bipolar Disorder
The U.S. Food and Drug Administration approved the first generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches. “Generic drugs undergo a rigorous scientific review to ensure...
Supplemental New Drug Application For Risperdal® Consta® Submitted To The FDA For The Treatment Of Bipolar Disorder
Alkermes, Inc. (NASDAQ: ALKS) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a supplemental New Drug Application (sNDA) for RISPERDAL® CONSTA® [(risperidone) Long-Acting Injection] to the U.S. Food and Drug Administration...
New Scholarship For Leaders Of Bipolar Lives
What do you do when you want to let the bipolar community know about scholarships for people with bipolar disorder, but soon discover that support for bipolar students is still far too rare? Why donate a scholarship yourself of course. The Bipolar Lives Scholarship is a new scholarship, created when...
Benefits Of Omega 3s Still Unclear For Bipolar Disorder
Despite intriguing findings that omega 3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega 3s are useful treatments for people with bipolar disorder, according to a review of recent studies. Nevertheless, omega 3s deserve further study,...